R&D重组小鼠CD19 Fc嵌合蛋白,CF

R&D重组小鼠CD19 Fc嵌合蛋白,CF(9730-CD)

产品简介：

规格：50 µg

纯度： >95%，在还原条件下通过SDS-PAGE测定，并用银染剂观察。

内毒素水平：通过LAL方法测定每1 μg蛋白质<1.0 EU。

活性：通过功能性ELISA中的结合能力来测量。当重组小鼠CD19 Fc嵌合体以2 µg/mL，100 µL每孔固定时，重组生物素化人CD81 Fc嵌合体的结合ED50为7-35 µg/mL。

来源：中国仓鼠卵巢细胞系，CHO衍生的小鼠CD19蛋白

Accession#：P25918

N-端序列：Arg19 和 Ser68

结构：二硫键连接的同型二聚体

预测分子量：57 kDa

SDS-PAGE：78-95 kDa，还原条件

形式：从0.2 µm过滤的PBS溶液中冻干。

复溶：在PBS中以500 μg/mL重新配制。

运输：产品在环境温度下运输。收到后，立即将其存放在下文建议的温度下。

储存/稳定性：避免重复冻融循环。复溶后，在无菌条件下2至8℃，1个月；-20至-70℃，3个月。

产品订购：

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.